Breaking News Instant updates and real-time market news.

LTHM

Livent

$13.07

0.28 (2.19%)

, TLRY

Tilray

$69.94

0.03 (0.04%)

08:45
03/12/19
03/12
08:45
03/12/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Livent (LTHM) 36.13% +2.06, Tilray (TLRY) 25.72% +0.34, CyberArk (CYBR) 0.44% +0.19, ProShares UltraShort Lehman 20 plus Year Treasury (TBT) 3.94% +0.09, Sea Limited (SE) 1.32% +0.06, Uniti Group (UNIT) 0.33% +0.06, ProShares UltraShort S&P 500 (SDS) 2.37% +0.05, Kandi Technologies (KNDI) 19.18% +0.04, Omeros (OMER) 3.15% +0.01, and Uxin Ltd (UXIN) 5.35% +0.01.

LTHM

Livent

$13.07

0.28 (2.19%)

TLRY

Tilray

$69.94

0.03 (0.04%)

CYBR

CyberArk

$110.80

3.95 (3.70%)

TBT

ProShares UltraShort 20+ yr Trsry

$35.18

0.25 (0.72%)

SE

Sea Limited

$23.31

-0.4 (-1.69%)

UNIT

Uniti Group

$8.52

0.21 (2.53%)

SDS

UltraShort S&P500 ProShares

$34.63

-1.03 (-2.89%)

KNDI

Kandi Technologies

$7.35

0.05 (0.68%)

OMER

Omeros

$16.27

0.46 (2.91%)

UXIN

Uxin

$4.87

0.09 (1.88%)

  • 12

    Mar

  • 14

    Mar

  • 15

    Mar

  • 18

    Mar

  • 16

    Apr

  • 01

    May

LTHM Livent
$13.07

0.28 (2.19%)

03/03/19
LOOP
03/03/19
NO CHANGE
Target $101
LOOP
Buy
FMC Corporation price target lowered to $101 from $118 at Loop Capital
Loop Capital analyst Chris Kapsch lowered his price target for FMC Corporation (FMC) to $101 from $118 to reflect the spin of Livent (LTHM). The analyst reiterates a Buy rating on FMC Corporation's shares.
03/01/19
LOOP
03/01/19
NO CHANGE
Target $18
LOOP
Buy
Livent long term growth story intact, says Loop Capital
Loop Capital analyst Chris Kapsch warns that Livent shares could experience some volatility in the next couple of days as the "remaining 85% of former parent ownership will be distributed to shareholders in a tax-free spin". The analyst is also keeping his Buy rating and $18 price target on the stock, saying Livent's loner-term growth story is not broken and that he would take advantage of any pullback.
02/28/19
SPHN
02/28/19
NO CHANGE
Target $95
SPHN
Overweight
FMC Corporation is best positioned ag input company, says Stephens
Stephens analyst Mark Connelly said FMC Corporation (FMC) has spent the last decade slimming down from a diversified chemical producer, to an ag, lithium, and food ingredient play and the spinoff of the remaining shares of Livent (LTHM), which occurs tomorrow, is the last step in this transformation. Ahead of the spin, he called FMC his top pick in the sector, calling it "the best positioned ag input company at a time when the ag cycle is rising and big M&A has left major competitors looking to redefine themselves." Connelly has a $95 price target and Overweight rating on stand-alone FMC.
02/27/19
02/27/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Algonquin Power (AQN) initiated with a Neutral at BofA/Merrill. 2. Bilibili (BILI) initiated with a Buy at China Renaissance. 3. Livent (LTHM) initiated with a Buy at Gabelli. 4. Champions Oncology (CSBR) initiated with a Buy at National Securities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
TLRY Tilray
$69.94

0.03 (0.04%)

03/08/19
JEFF
03/08/19
INITIATION
Target $61
JEFF
Underperform
Tilray initiated with an Underperform at Jefferies
Jefferies analyst Owen Bennett started Tilray with an Underperform rating and $61 price target. The analyst says he struggles to justify the current valuation given Tilray's "arguably inferior positioning in parts of its business" relative to peers. The company is "too dependent on an unclear medical outlook," Bennett tells investors in a research note.
03/08/19
JEFF
03/08/19
INITIATION
Target $61
JEFF
Underperform
Tilray falls after Jefferies starts with Underperform rating, $61 target
Shares of Tilray (TLRY) are moving lower after Jefferies analyst Owen Bennett initiated coverage of the shares with an Underperform rating and $61 price target. Underperform is Jefferies' equivalent of a sell rating. Shares of Tilray are down 4%, or $2.97, to $66.75 in premarket trading. Bennett's 10-year discounted cash flow-driven valuation suggests the stock is "too expensive for its outlook." As a company wanting to be a global leader, the names that Tilray needs to be compared to are Canopy Growth (CGC) and Aurora Cannabis (ACB), Bennett tells investors in a research note. However, Tilray's Canada medical share is not in the top four and recent consumer feedback is "not inspiring," adds the analyst. Further, he believes the company's approach to recreational "does not appear as well thought through" and that its "optionality" in the U.S. is "less impressive." As such, Bennett struggles to justify Tilray's current valuation.
03/04/19
PIPR
03/04/19
NO CHANGE
PIPR
Piper Jaffray sees continued medical cannabis growth
Piper Jaffray analyst Michael Lavery writes that his discussions with a medical pain specialist in New York affirm his expectations of continued growth for medical cannabis, particularly as practitioners search for opioid alternatives. With over 30 U.S. states now in favor of medical use of marijuana, the analyst believes that the national prohibition will end in the next few years with the "STATES Act or federal legalization". Lavery is positive on Tilray (TLRY) and its partnership with Novartis (NVS) to develop and distribute medical cannabis products, keeping his Overweight rating and $90 price target on the shares. The analyst also calls GW Pharma (GWPH) a "trailblazer for developing cannabis-derived products for medical use", with its FDA-approved epidiolex cannabidiol product, keeping his Overweight rating and $195 price target on the stock. Lavery further maintains his Overweight rating and $60 price target on Canopy Growth (CGC) given its current valuation.
03/08/19
03/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tilray (TLRY) initiated with an Underperform at Jefferies. 2. BB&T (BBT) initiated with a Buy at Odeon Capital. 3. Syros Pharmaceuticals (SYRS) initiated with an Outperform at JMP Securities. 4. W&T Offshore (WTI) initiated with a Buy at Stifel. 5. Ichor Holdings (ICHR) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CYBR CyberArk
$110.80

3.95 (3.70%)

01/23/19
MSCO
01/23/19
NO CHANGE
MSCO
CyberArk, Proofpoint, Tenable among Morgan Stanley's cybersecurity Q4 top picks
Morgan Stanley analyst Melissa Franchi sees a largely favorable setup for cybersecurity companies into fourth quarter results, noting that her conversations with channel partners and the firm's reseller and CIO surveys point to a healthy close to the quarter and a stable, durable demand environment in 2019. She names CyberArk (CYBR), Proofpoint (PFPT) and Tenable (TENB) as top picks for Q4. Franchi notes that her checks suggest a healthy demand environment, continued improved execution and improved product positioning for CyberArk; Proofpoint is seeing some maturity in its core email security market, but this is already in investor sentiment, while she is hearing some positive momentum with some of its newer products; and on Tenable, she thinks it should more than benefit from the growing priority of vulnerability management and an underpenetrated base. Healthy demand trends seen in her firewall checks help to affirming Palo Alto Networks (PANW) as a top pick, but also position Fortinet (FTNT) for a "better than feared" quarter, Franchi adds in her sector preview note.
01/16/19
STFL
01/16/19
NO CHANGE
STFL
Checks show firewall spending remains 'robust,' says Stifel
Stifel analyst Gur Talpaz said his latest quarterly survey of 30 North American security-centric resellers left him "cautiously encouraged" about the overall security spending environment, particularly within the firewall space. Despite recent fears about an imminent slowdown in firewall spending, his checks point to a "robust" deal pipeline through 2019, particularly for Palo Alto Networks (PANW), Talpaz tells investors. Outside of Palo Alto, Talpaz also said he is "more optimistic" on Check Point (CHKP) than he has been "in some time." While he also noted that the was "generally pleased" that the number of resellers pointing to a decline in their Proofpoint (PFPT) business improve to the best level seen in 2018, Talpaz continues to see "work to be done." Others in the cybersecurity space include Rapid7 (RPD), FireEye (FEYE), Fortinet (FTNT), Symantec (SYMC) and CyberArk (CYBR).
02/15/19
WEDB
02/15/19
NO CHANGE
Target $130
WEDB
Outperform
CyberArk price target raised to $130 from $95 at Wedbush
Wedbush analyst Daniel Ives reiterated an Outperform rating on CyberArk and raised his price target to $130 from $95 after the company "closed out 2018 like Mayweather," beating Street expectations and giving guidance that was about 5% ahead of the Street on the top-line. In a research note to investors, Ives says yesterday's results, along with his continued robust checks, give him increased confidence in CyberArk's "strong" product portfolio and leadership position in the PAM market.
02/14/19
JPMS
02/14/19
NO CHANGE
Target $104
JPMS
Overweight
JPMorgan calls CyberArk earnings 'most impressive,' ups target to $104
JPMorgan analyst Sterling Auty says CyberArk reported the most impressive report so far in December quarter earnings of the names he covers. He likes the company's "growing importance" to its core resellers and upped his price target for the shares to $104.
TBT ProShares UltraShort 20+ yr Trsry
$35.18

0.25 (0.72%)

SE Sea Limited
$23.31

-0.4 (-1.69%)

03/04/19
STFL
03/04/19
NO CHANGE
Target $27
STFL
Buy
Sea Limited deal-related weakness a buying opportunity, says Stifel
Stifel analyst Scott Devitt noted that weakness in shares of Sea Limited is being driven by a 50M share offering that was announced Friday after the close and is expected to price on Wednesday. While Sea Limited's proposed offering would be up to 13% dilutive to the company's fully-diluted total shares outstanding, he views the deal-related weakness as a buying opportunity as Devitt believes the funds raised should allow the company to achieve profitability without additional need for more external capital. Garena's implied $4.5B valuation and Shopee's implied valuation of under $5B at aftermarket prices on Friday are "well below" multiples for high-growth marketplace comps, said Devitt, who keeps a Buy rating and $27 price target on Sea Limited shares.
02/01/19
MSCO
02/01/19
NO CHANGE
MSCO
Overweight
Sea Limited named a long Research Tactical Idea at Morgan Stanley
02/27/19
PIPR
02/27/19
NO CHANGE
Target $25
PIPR
Overweight
Sea Limited price target raised to $25 from $18 at Piper Jaffray
Piper Jaffray analyst Michael Olson raised his price target for Sea Limited to $25 saying the company had a "strong" Q4 with revenue and adjusted EBITDA ahead of plan. The combination of GDP and connectivity growth, along with a "secular rising tide" in Sea Limited's core verticals of online gaming, e-commerce, digital payments, will drive "strong near-term growth, followed by material long-term profitability," Olson tells investors in a post-earnings research note. He maintains an Overweight rating on the shares.
11/21/18
PIPR
11/21/18
NO CHANGE
Target $18
PIPR
Overweight
Sea Limited posted 'strong' Q3 results, says Piper Jaffray
Piper Jaffray analyst Michael Olson says Sea Limited had a "strong" Q3 with revenue and adjusted EBITDA ahead of plan. The combination of GDP and connectivity growth, along with a "secular rising tide" in the company's core verticals, will drive "strong" near-term growth, followed by "material" long-term profitability, Olson tells investors in a post-earnings research note. He lowered his price target for the shares to $18 from $19 on his sum-of-the-parts valuation but maintains an Overweight rating on Sea Limited.
UNIT Uniti Group
$8.52

0.21 (2.53%)

03/05/19
WELS
03/05/19
DOWNGRADE
WELS
Underperform
Uniti Group downgraded to Underperform from Market Perform at Wells Fargo
02/26/19
MSCO
02/26/19
NO CHANGE
Target $7
MSCO
Underweight
Uniti Group price target lowered to $7 from $16 at Morgan Stanley
Morgan Stanley analyst Simon Flannery stated in a note issued prior to Windstream (WIN) confirming that it has filed for Chapter 11 bankruptcy that he sees several potential outcomes for the company's relationship with Uniti Group (UNIT) in the event that Windstream seeks bankruptcy protection. The four potential outcomes he envisions include: the lease is accepted by the court; the lease is rejected; the lease is renegotiated; or the sale and leaseback structure is challenged and the structure collapses back to a single company. In his base case, Flannery is assuming Uniti cuts its annual dividend to 80c from $2.40 and he said Uniti's ability to do additional transactions is now complicated by the Windstream overhang. He maintains an Underweight rating on Uniti shares and cut his price target on the stock to $7 from $16.
03/05/19
03/05/19
DOWNGRADE
Target $8

Underperform
Uniti Group downgraded to Underperform on too much uncertainty at Wells Fargo
As previously reported, Wells Fargo analyst Jennifer Fritzsche downgraded Uniti Group (UNIT) to Underperform from Market Perform and lowered her price target on the shares to $8 from $17. The analyst notes that the company released an 8K which indicated a significant cut in the dividend. Fritzsche believes the February 15 ruling against Windstream (WIN) in its case versus Aurelius Capital Management, and the ripple effect on Uniti including a delay of the company's Q4 earnings and potential default in its credit agreement, has introduced a great degree of uncertainty into the story. While the analyst continues to believe Uniti's fiber assets are attractive, the company's path toward diversifying away from its Windstream exposure has become more difficult to model.
03/05/19
03/05/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Uniti Group (UNIT) downgraded to Underperform from Market Perform at Wells Fargo with analyst Jennifer Fritzsche saying the company released an 8K which indicated a significant cut in the dividend. 2. Adamas Pharmaceuticals (ADMS) downgraded to Underperform from Neutral at Mizuho, to Market Perform from Outperform at Cowen, and to Hold from Buy at Needham. 3. SQM (SQM) downgraded to Neutral from Buy at Citi with analyst Andrew McCarthy saying he continues to like the long-term lithium demand story but does not expect share price outperformance over the next 12 months. 4. Orange SA (ORAN) downgraded to Equal Weight from Overweight at Barclays with analyst Mathieu Robilliard saying an "irrational level of promotions" in 2018 continue to weigh on French telecoms. 5. Inter Parfums (IPAR) downgraded to Neutral from Buy at DA Davidson with analyst Linda Bolton Weiser citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SDS UltraShort S&P500 ProShares
$34.63

-1.03 (-2.89%)

KNDI Kandi Technologies
$7.35

0.05 (0.68%)

OMER Omeros
$16.27

0.46 (2.91%)

03/23/18
HCWC
03/23/18
NO CHANGE
Target $34
HCWC
Buy
Omeros price target raised to $34 from $30 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Omeros to $34 after Omidria pass-through reimbursement status was extended. The language in the spending bill provides the extension for a period of two years, Selvaraju tells investors in a research note. This is an "unexpected success" for Omeros, and should lead to a "significant rebound" in Omidria sales and resumption of growth in the franchise, Selvaraju writes. He reiterates a Buy rating on Omeros shares.
07/12/18
GHSC
07/12/18
INITIATION
Target $30
GHSC
Buy
Omeros initiated with a Buy at Seaport Global
Seaport Global analyst Corey Davis initiated Omeros with a Buy and $30 price target saying Omidria for cataract surgery regains pass-through starting October 1 following new legislation. Davis expects the company to quickly return to an annualized run-rate of $87M, and if it secures permanent reimbursement from CMS, likely $200M-$400M in peak sales.
10/15/18
HCWC
10/15/18
NO CHANGE
Target $34
HCWC
Buy
Omeros selloff on data brings attractive entry point, say H.C. Wainwright
Data released earlier this month from a Phase 2 trial of OMS721, Omeros's most advanced clinical candidate, appear to have created some confusion in the market as the company's share price has fallen roughly 50% since the announcement, H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. The selloff is unwarranted, says the analyst, who reiterates a Buy rating on the shares with a $34 price target. He points out that the data were from a small trial that was not designed to deliver statistical significance or definitive evidence of efficacy. Further, the "data itself were encouraging, not discouraging, and there certainly was no evidence of any safety concern or toxicity issue that would have jeopardized OMS721's future development," Selvaraju writes.
03/23/18
WEDB
03/23/18
DOWNGRADE
Target $19
WEDB
Neutral
Omeros downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Liana Moussatos downgraded Omeros to Neutral and lowered her price target for the shares to $19 from $47. The analyst sees a "lack of clarity for the financial status" with disruption in Omidria sales and the company's inability to fund progress with its top potential value driver OMS721. Even with possible extension of Omidria pass-through reimbursement for two additional years starting in October 2018, sales are unlikely to fund the pipeline in 2018 and 2019, Moussatos tells investors in a research note. Omeros closed yesterday up 35%, or $4.11, to $15.75.
UXIN Uxin
$4.87

0.09 (1.88%)

01/10/19
JPMS
01/10/19
UPGRADE
JPMS
Overweight
Uxin upgraded to Overweight from Neutral at JPMorgan
01/15/19
JPMS
01/15/19
NO CHANGE
Target $7
JPMS
Overweight
JPMorgan reiterates call for 100% upside in Uxin shares
In a research note titled "A great start in 2019; Reiterate 100% upside," JPMorgan analyst Nick Lai says Uxin yesterday reported "very strong" December year-over-year transaction growth of 44%. Contrary to a "miserable new car market" in China, the used car market has performed well, up 13% last year and is expected to continue its double-digit growth rate in 2019 and 2020, Lai tells investors in a research note. He calls Uxin a leader in China's e-commerce used car market. The analyst still sees 100% upside potential in Uxin shares and keeps an Overweight rating on the name with a $7 price target.
01/10/19
JPMS
01/10/19
UPGRADE
Target $7
JPMS
Overweight
JPMorgan upgrades Uxin to Overweight with 100% potential upside
JPMorgan analyst Nick Lai upgraded Uxin to Overweight from Neutral while lowering his price target for the shares to $7 from $7.40. The stock closed yesterday up 34c to $3.55. The analyst sees 100% potential share upside amid continued growth in China's used car demand. Uxin has the largest used car e-commerce platform in China.
12/21/18
GSCO
12/21/18
DOWNGRADE
Target $9.3
GSCO
Neutral
Uxin downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Ronald Keung downgraded Uxin to Neutral while raising his price target for the shares to $9.30 from $9.10. The analyst cites valuation for the downgrade following the recent rally in the shares.

TODAY'S FREE FLY STORIES

21:25
03/25/19
03/25
21:25
03/25/19
21:25
General news
Fed's Rosengren warned that U.S. Q1 growth is likely to be weak »

Fed's Rosengren…

BBBY

Bed Bath & Beyond

$13.87

0.17 (1.24%)

20:44
03/25/19
03/25
20:44
03/25/19
20:44
Periodicals
Activist firms seek to replace Bed Bath & Beyond board, CEO, WSJ says »

Activist funds -Legion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Apr

RTN

Raytheon

$180.58

-0.82 (-0.45%)

, BA

Boeing

$370.52

8.37 (2.31%)

20:36
03/25/19
03/25
20:36
03/25/19
20:36
Hot Stocks
Raytheon kill vehicle hits ICBM target in first dual-salvo test »

For the first time, the…

RTN

Raytheon

$180.58

-0.82 (-0.45%)

BA

Boeing

$370.52

8.37 (2.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

20:35
03/25/19
03/25
20:35
03/25/19
20:35
General news
The "Summary of Opinions" from the BoJ's March meeting »

The "Summary of…

WHD

Cactus

$36.03

1.225 (3.52%)

20:27
03/25/19
03/25
20:27
03/25/19
20:27
Hot Stocks
Cactus VP of Operations sells 229K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$56.67

-0.065 (-0.11%)

, MKC

McCormick

$143.88

1.58 (1.11%)

20:25
03/25/19
03/25
20:25
03/25/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CCL

Carnival

$56.67

-0.065 (-0.11%)

MKC

McCormick

$143.88

1.58 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 26

    Mar

  • 27

    Mar

CRTO

Criteo

$21.99

-3.4 (-13.39%)

20:19
03/25/19
03/25
20:19
03/25/19
20:19
Downgrade
Criteo rating change at KeyBanc »

Criteo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

$0.00

(0.00%)

20:02
03/25/19
03/25
20:02
03/25/19
20:02
Periodicals
Samsung sees weaker environment for display, memory in Q1, Bloomberg says »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$370.52

8.37 (2.31%)

19:51
03/25/19
03/25
19:51
03/25/19
19:51
Hot Stocks
U.S. MDA and Boeing Complete Historic Missile Defense Test »

The U.S. Missile Defense…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

MCD

McDonald's

$185.66

-1.11 (-0.59%)

19:49
03/25/19
03/25
19:49
03/25/19
19:49
Periodicals
McDonald's purchase price of Dynamic Yield above $300M, Bloomberg says »

The purchase of Dynamic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 28

    May

SSNLF

Samsung

$0.00

(0.00%)

19:32
03/25/19
03/25
19:32
03/25/19
19:32
Periodicals
Breaking Periodicals news story on Samsung »

Samsung sees Q1 below…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWR

American States Water

$71.51

0.505 (0.71%)

19:22
03/25/19
03/25
19:22
03/25/19
19:22
Hot Stocks
American States Water CEO sells 12.4K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$56.35

-1.38 (-2.39%)

19:10
03/25/19
03/25
19:10
03/25/19
19:10
Hot Stocks
Methanex confirms receipt of director nominees notice from M&G »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$34.14

0.81 (2.43%)

, SAEX

SAExploration

$4.03

0.13 (3.33%)

18:55
03/25/19
03/25
18:55
03/25/19
18:55
Hot Stocks
Fly Intel: After Hours Movers »

DOWN AFTER EARNINGS:…

BECN

Beacon Roofing

$34.14

0.81 (2.43%)

SAEX

SAExploration

$4.03

0.13 (3.33%)

IQ

iQIYI

$24.01

-0.86 (-3.46%)

MYOK

MyoKardia

$51.87

-2.44 (-4.49%)

CTMX

CytomX Therapeutics

$10.76

0.33 (3.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 26

    Mar

  • 21

    May

  • 27

    Mar

HPQ

HP Inc.

$18.97

-0.4 (-2.07%)

18:48
03/25/19
03/25
18:48
03/25/19
18:48
Periodicals
HP lawyer tells court Autonomy's Lynch inflated sales data, Reuters says »

A lawyer for HP told a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

PEGA

Pegasystems

$63.61

-0.27 (-0.42%)

18:45
03/25/19
03/25
18:45
03/25/19
18:45
Hot Stocks
Pegasystems CEO: We are massively changing our marketing strategy »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

SMTC

Semtech

$52.59

-0.38 (-0.72%)

18:32
03/25/19
03/25
18:32
03/25/19
18:32
Hot Stocks
Semtech CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

TMO

Thermo Fisher

$268.89

5.015 (1.90%)

18:24
03/25/19
03/25
18:24
03/25/19
18:24
Hot Stocks
Thermo Fisher CEO: We have a very disciplined M&A process »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

18:24
03/25/19
03/25
18:24
03/25/19
18:24
Periodicals
Parliament forces votes on Brexit plan options, Bloomberg reports »

Lawmakers of U.K.…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.99

-0.56 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$185.66

-1.11 (-0.59%)

18:23
03/25/19
03/25
18:23
03/25/19
18:23
Hot Stocks
McDonald's to acquire Dynamic Yield, terms not stated »

McDonald's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 28

    May

BA

Boeing

$370.52

8.37 (2.31%)

18:22
03/25/19
03/25
18:22
03/25/19
18:22
Periodicals
Boeing software fix to prevent repeated activiation of MCAS, Reuters says »

A Boeing software repair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

ACHC

Acadia

$29.47

-0.59 (-1.96%)

17:58
03/25/19
03/25
17:58
03/25/19
17:58
Hot Stocks
Acadia says President Brett Turner leaving by mutual agreement »

Brent Turner, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.78

-2.33 (-1.22%)

17:41
03/25/19
03/25
17:41
03/25/19
17:41
Recommendations
Apple analyst commentary at Piper Jaffray »

Apple price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

ZFGN

Zafgen

$2.70

-0.15 (-5.26%)

17:38
03/25/19
03/25
17:38
03/25/19
17:38
Hot Stocks
Armistice Capital reports 5.6% passive stake in Zafgen »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$268.56

0.27 (0.10%)

17:36
03/25/19
03/25
17:36
03/25/19
17:36
Hot Stocks
Northrop Grumman awarded $245.05M Navy contract modification »

Northrop Grumman has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.